MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics - Summary - MDSpire

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • By

  • Rocío Maseda

  • María Carmen Arriba

  • Lucía Martínez-Santamaría

  • Eva Jiménez

  • Sara Herráiz-Gil

  • Nuria Illera

  • Lucía Quintana-Castanedo

  • Marta García

  • Susana Suárez-Sancho

  • Rosa Yáñez

  • Isabel Pérez-Conde

  • Marta Carretero

  • Magdalena Martínez-Queipo

  • Raquel de Paz

  • Carlos León

  • Víctor Jiménez-Yuste

  • Alberto M. Borobia

  • Ángeles Vicente

  • Su M. Lwin

  • John A. McGrath

  • María Eugenia Fernández-Santos

  • Nora Butta

  • Rosa Sacedón

  • Marcela del Río

  • Raúl de Lucas

  • María José Escámez

  • May 5, 2026

  • 0 min

Share

Objective:

To evaluate the safety and efficacy of haploidentical bone marrow-derived mesenchymal stem cells (BM-MSC) as a monotherapy for recessive dystrophic epidermolysis bullosa (RDEB), with a focus on their anti-inflammatory potential as a primary aim.

Key Findings:
  • MSC therapy was well-tolerated without serious adverse events.
  • Long-term pruritus, sleep, and fatigue were globally reduced.
  • In 7/8 patients, at least one key domain (disease severity, pruritus, or inflammation) significantly improved, with responses correlating with dynamics of sCD40L and MCP1.
  • Altered immune cell subsets were observed, but did not consistently distinguish responders.
Interpretation:

BM-MSC is a safe and potentially effective anti-inflammatory intervention that mitigates systemic inflammatory markers during RDEB progression, with MCP1 and sCD40L serving as potential predictive biomarkers, highlighting the need for further research.

Limitations:
  • Small sample size with only eight patients completing the study.
  • Lack of consistent durable engraftment or sustained collagen VII deposition.
  • Absence of a control group limits the ability to draw definitive conclusions.
Conclusion:

Findings support the use of haploidentical BM-MSC as a complementary strategy in RDEB management, providing insights into individual variability and therapeutic responsiveness.

Original Source(s)

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics

  • by Rocío Maseda, María Carmen Arriba, Lucía Martínez-Santamaría, Eva Jiménez, Sara Herráiz-Gil, Nuria Illera, Lucía Quintana-Castanedo, Marta García, Susana Suárez-Sancho, Rosa Yáñez, Isabel Pérez-Conde, Marta Carretero, Magdalena Martínez-Queipo, Raquel de Paz, Carlos León, Víctor Jiménez-Yuste, Alberto M. Borobia, Ángeles Vicente, Su M. Lwin, John A. McGrath, María Eugenia Fernández-Santos, Nora Butta, Rosa Sacedón, Marcela del Río, Raúl de Lucas, María José Escámez

  • May 5, 2026

Related Content

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Biotech exec Jeremy Levin on the industry’s strategic turning point